Reviewed by Nabus Research · last reviewed 2026-07-12 · about our review process

○ Human lifespan evidence: none

Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

What it is

Class: Adeno-associated-virus vector expressing TERT (preclinical)

Also known as: AAV9-Tert, AAV-TERT, telomerase gene therapy

Relationship to telomere biology: Telomerase gene therapy delivers the TERT gene via an AAV vector so that treated cells express telomerase and extend their telomeres. It is the intervention behind the striking mouse-lifespan result — but there is NO human evidence, so it sits at animal grade only.

Regulatory status

Preclinical/experimental. There is no approved telomerase gene therapy and no human trial for aging. Any human application would face the telomerase–cancer-risk question directly.

Mechanism

In mice, a single AAV9-TERT treatment in adult/old animals lengthened telomeres, delayed several aging phenotypes, and increased lifespan without a reported rise in cancer incidence (Bernardes de Jesus/Blasco 2012); a related mouse study showed benefit in a short-telomere pulmonary-fibrosis model (Povedano/Blasco 2018). See /telomerase-cancer-paradox.

Animal lifespan evidence

Animal lifespan evidence: yes

A single intravenous dose of AAV9-TERT in adult and aged mice increased median lifespan and delayed several age-related conditions, without increased cancer incidence in that study (Bernardes de Jesus et al., EMBO Mol Med 2012;4(8):691-704). A mouse gene therapy, not an approved human treatment.

This is separate from human lifespan evidence, which is none for every intervention on this site. A mouse lifespan result is not a human lifespan result, and a telomere change is not a lifespan result in either species.

Evidence — Animal (mouse lifespan / disease model) verify: verified against primary source

Species / population	Adult (1-year) and old (2-year) mice; and a separate bleomycin/short-telomere mouse model of pulmonary fibrosis.
Exposure, route, schedule	Single intravenous dose of an AAV9 vector expressing mouse TERT (AAV9-Tert).
Comparator / duration	AAV9 empty-vector / untreated controls.
Endpoint / numeric result	Median lifespan increased ~24% when treated at 1 year and ~13% when treated at 2 years, with delayed aging markers and NO reported increase in cancer incidence (2012); improved lung function and reduced fibrosis in the pulmonary-fibrosis model (2018).
What it did NOT establish	These are mouse results. Mouse telomere biology differs substantially from human; there is no human lifespan, disease-outcome, or safety evidence, and the cancer-risk question is unresolved in humans.

Negative or null findings

No human data of any kind — the entire evidence base is preclinical (mouse).
Mouse telomeres are much longer than human telomeres and mouse cells regulate telomerase differently, so the lifespan result does not transfer to a human claim.

Telomerase gene therapy (AAV-TERT)